Product image of Letrozol Accord (Letrozole) supplied by GNH India

Letrozol Accord

Active Ingredient:
Letrozole
Origin:
EU

Letrozol Accord (Letrozole)

Letrozole, the active ingredient in Letrozol Accord, is an aromatase inhibitor presented as an oral tablet for oral use. It is employed in the endocrine therapy of hormone‑receptor positive breast cancer in postmenopausal women, reducing estrogen production that can fuel tumor growth.

GNH India supplies Letrozol Accord as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres, pharmacies and clinics worldwide. The company adheres to stringent quality standards and provides reliable logistics for global distribution, ensuring product integrity throughout the supply chain.

Manufacturer / TM Owner

Accord Healthcare S.L.U.

1
Pack/s
This product is added to your enquiry list

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

A minimum order value applies. Our team will confirm the exact amount or quantity after reviewing your requirements.

Indications & Clinical Uses

Letrozole is used in the endocrine therapy of hormone‑receptor positive breast cancer, acting on estrogen‑dependent tumor pathways.

  • Early‑stage hormone‑receptor positive breast cancer: reduces risk of recurrence after surgery.
  • Metastatic hormone‑receptor positive breast cancer: slows disease progression in postmenopausal patients.
  • Adjuvant therapy following tamoxifen: provides continued estrogen suppression after initial treatment.

How It Works

  • Letrozole reversibly binds to the aromatase enzyme (CYP19A1) in peripheral tissues, inhibiting the conversion of androstenedione and testosterone to estrone and estradiol. By lowering circulating estrogen levels, it deprives estrogen‑dependent breast cancer cells of a growth stimulus, thereby inhibiting tumor proliferation. The inhibition is dose‑dependent and sustained, leading to a profound and persistent reduction of estrogen concentrations in postmenopausal women, while having minimal effect on adrenal androgen production.

Side Effects

Letrozole may be associated with a range of adverse reactions, varying from mild to serious.

Common Side Effects

  • Hot flashes: transient feeling of warmth and sweating.
  • Joint and muscle pain: arthralgia or myalgia.
  • Nausea: mild to moderate upset stomach.
  • Fatigue: persistent lack of energy.
  • Headache: mild to moderate cranial discomfort.
  • Dizziness: sensation of light‑headedness.

Serious or Rare Side Effects

  • Osteoporosis and fractures: decreased bone mineral density leading to fractures.
  • Severe liver injury: marked elevation of transaminases or hepatitis.
  • Thromboembolic events: pulmonary embolism or deep vein thrombosis.
  • Allergic reactions (anaphylaxis): severe hypersensitivity requiring immediate medical attention.
  • Severe hypertension: significant increase in blood pressure that may require treatment.

Precautions & Warnings

When prescribing Letrozole, clinicians should consider several precautionary measures to ensure patient safety.

  • Assess bone health: evaluate risk of osteoporosis before initiating therapy.
  • Monitor liver function: perform baseline and periodic liver enzyme tests.
  • Check cardiovascular status: screen for hypertension or thrombotic risk.
  • Review concomitant medications: avoid drugs that may increase estrogen levels.
  • Pregnancy and lactation: contraindicated in pregnancy; advise effective contraception.
  • Store at ambient temperature: keep below 25 °C in original packaging, protect from moisture.

Avoid Interactions

Letrozole can interact with other medicines, influencing its efficacy or safety.

Major Interactions (Avoid)

  • Strong CYP3A4 inducers (e.g., rifampin, carbamazepine): may reduce letrozole plasma levels.
  • Estrogen‑containing hormonal therapies (e.g., hormone replacement therapy): counteract aromatase inhibition.

Moderate Interactions (Monitor Closely)

  • Anticoagulants (warfarin): may increase bleeding risk; monitor INR.
  • Selective serotonin reuptake inhibitors (SSRIs): potential for altered metabolism; observe clinical response.
  • Tamoxifen: concurrent use may diminish therapeutic effect; consider sequencing.

Frequently Asked Questions

Letrozol Accord contains letrozole, an aromatase inhibitor indicated for the endocrine treatment of hormone‑receptor positive breast cancer in postmenopausal women. It is used in both early‑stage (adjuvant) and metastatic settings to lower estrogen levels that can stimulate tumor growth.

Letrozole blocks the aromatase enzyme (CYP19A1), which converts androgens into estrogens in peripheral tissues. By inhibiting this conversion, circulating estrogen concentrations fall, depriving estrogen‑dependent breast cancer cells of a key growth signal and thereby slowing tumor proliferation.

The prescribed dose of Letrozol Accord is determined by the treating physician based on the patient’s clinical condition, disease stage, and individual tolerance. Specific dosing regimens are not disclosed here and should follow the prescriber’s instructions.

Letrozole is contraindicated in pregnancy because it can interfere with fetal development. Women of child‑bearing potential should use effective contraception during treatment. Breastfeeding is not recommended, as the drug may pass into milk and affect the infant.

To place an order, submit an enquiry on the Letrozol Accord product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Letrozol Accord (letrozole) is a third‑generation aromatase inhibitor with a high potency and a long half‑life, often considered slightly more effective at suppressing estrogen than anastrozole. Compared with tamoxifen, a selective estrogen receptor modulator, letrozole provides deeper estrogen depletion but lacks tamoxifen’s partial agonist activity in bone and uterine tissue.

Letrozol Accord tablets should be stored at ambient temperature, preferably below 25 °C. Keep them in the original blister pack, protect from moisture and direct sunlight, and ensure the container is tightly closed to maintain product stability.

Letrozol Accord is taken orally, usually as a whole tablet swallowed with water. It is generally administered once daily, preferably at the same time each day, and can be taken with or without food as advised by the prescriber.

The most serious adverse events include significant bone loss leading to osteoporosis and fractures, severe liver injury such as hepatitis, and thromboembolic complications like deep‑vein thrombosis or pulmonary embolism. Patients should be monitored regularly for these conditions.

Letrozol Accord should not be used in premenopausal women, pregnant or breastfeeding individuals, patients with severe hepatic impairment, or those with a known hypersensitivity to letrozole or any excipients. Caution is also advised for patients with a history of osteoporosis or thromboembolic disease.

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated:

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.

Related Products

Other formulations containing Letrozole

A

A
A

A
A

A
A

A

Browse all products →

Ordering Process

Simple, Secure, and Seamless

Learn how our streamlined ordering process guarantees fast, compliant, and reliable access to essential medicines worldwide.

Quote request form

01

Submit Quote Request Form

Tell us what medications you need by filling out our simple form and uploading a valid document.

Price estimate review

02

We Review & Send Estimate

Our licensed pharmacists will verify your details and provide you with a detailed cost estimate.

Secure payment

03

Confirm & Make Payment

Discuss any queries, approve the estimate, and complete your payment.

Worldwide delivery

04

Get Delivered

Your medicines, safely packed and delivered to your door or nearest airport — hassle-free.

Regulatory recognitions

Quality You Can Trust

Our internationally recognized certifications underscore our commitment to safety, quality, and excellence.

SGS GSDP Certification

GSDP Compliant from SGS

URS ISO 9001

URS ISO 9001 Certification

FDA Maharashtra

Licensed by FDA Maharashtra

IEC License DGFT

IEC License issued by DGFT